INOZYME PHARMA INC. - COMMON STOCK

Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights

09 11 2021 16:05:03 提供 Nasdaq GlobeNewswire

Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting

04 10 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

22 9 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights

11 8 2021 06:00:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

04 8 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

21 7 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources

13 7 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency

09 6 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights

12 5 2021 06:00:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

07 5 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma to Present at the BofA Securities 2021 Virtual Healthcare Conference

06 5 2021 07:30:01 提供 Nasdaq GlobeNewswire

Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency

29 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences

28 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

14 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting

08 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Expands its Scientific Advisory Board

01 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights

25 3 2021 06:00:00 提供 Nasdaq GlobeNewswire

The Balancing Act® on Lifetime to Feature ENPP1 Deficiency

11 3 2021 07:30:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer

04 2 2021 06:00:00 提供 Nasdaq GlobeNewswire

Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

04 1 2021 06:00:00 提供 Nasdaq GlobeNewswire